The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). With the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.
28 February 2017
Tekcapital plc
("Tekcapital" or the "Company")
BELLUSCURA LTD ANNOUNCES OXYGEN CONCENTRATOR LICENSE AND DEVELOPMENT AGREEMENT
Tekcapital plc (AIM: TEK), an international provider of technology and intellectual property services, announces that Belluscura Ltd ("Belluscura") has signed a co-exclusive license and development agreement with Separation Design Group ("SDG") to develop a next generation portable oxygen concentrator ("POC"). As part of the agreement, Belluscura has licensed a portfolio of six intellectual properties from SDG1 and has agreed to provide monthly funding towards the development of a prototype POC device.
A POC is a device used to deliver concentrated oxygen to a patient requiring oxygen therapy. POCs are typically prescribed to people suffering from chronic obstructive pulmonary disease ("COPD"). The World Health Organization has estimated that 64 million people are suffering from moderate to severe COPD around the world2. POCs are generally considered a safer, less expensive and more convenient treatment for COPD compared to traditional compressed oxygen cylinders3. Ambulatory patients can benefit from greater personal freedom, with most airlines permitting their use during flight. The US Federal Aviation Authority requires all airlines landing in the USA to permit the use of approved POCs4.
SDG is a leading research laboratory in the field of oxygen concentrators. The Directors believe that the license should allow Belluscura to access and develop a next generation POC based on SDG's significant intellectual property portfolio, covering such features as oxygen enrichment, portability, oxygen conditioning and convenient and cost-effective maintenance.
Bob Rauker, Belluscura's CEO said: "We are delighted to enter into this license and development agreement. With the portable oxygen concentrator market expected to nearly double to $2.2bn by 20215, we believe that this opportunity has the potential to advance Belluscura's mission of investing in undervalued technology in order to provide premium medical devices at affordable prices."
About Belluscura:
Belluscura Limited is a global medical device company founded in in Oxford, England. Its mission is to make healthcare more affordable for patients and their providers by providing proprietary medical devices across a wide variety of treatment and diagnostic disciplines. Belluscura's products were originally developed by leading medical device companies or research centres, and with its unique business model it is able to offer these devices at affordable prices. To learn more about Belluscura please visit www.belluscura.com.
Tekcapital owns approximately 65% of the share capital of Belluscura.
For further information, please contact:
Tekcapital Plc |
|
Clifford M. Gross, Ph.D. |
[email protected] |
Allenby Capital Limited (Nominated Adviser & Joint Broker) |
+44 (0) 20 3328 5656 |
Jeremy Porter / Alex Brearley |
|
|
|
Dowgate Capital Stockbrokers (Joint Broker) |
+44 (0) 1293 517744 |
David Poutney / James Serjeant |
|
|
|
Walbrook PR Ltd |
+44 (0) 20 7933 8780 |
Paul Cornelius / Helen Cresswell / Sam Allen |
[email protected] |
Tekcapital plc - The World's Largest University Network for Open Innovation
Tekcapital helps clients profit from new, university-developed intellectual properties. With its proprietary discovery search engine, linked to 4,500+ universities in 160 countries, coupled with expert scientific review, Tekcapital provides a turn-key service to make it easy for clients to find and acquire the IP, analytics and technology transfer professionals they need to create a competitive advantage. Tekcapital plc is quoted on the AIM market of the London Stock Exchange (AIM: symbol TEK) and is headquartered in Oxford, in the UK. For more information, please visit www.tekcapital.com
LEI: 213800GOJTOV19FIFZ85 |
|
Note 1
Patent Number |
Priority Date (P) |
Title |
US 9,199,055 B2 |
P 11/24/2009 |
Ultra Rapid Cycle Portable Oxygen Concentrator |
US 8,894,751 B2 |
P 11/24/2009 |
Ultra Rapid Cycle Portable Oxygen Concentrator |
US Patent Application 14/876,133 |
P 11/24/2009 |
Ultra Rapid Cycle Portable Oxygen Concentrator |
US 8,888,902 |
8/15/2012 |
Portable Oxygen Enrichment Device and Method of Use |
US 8,500,852 |
4/30/2007 |
Sorption Method, Device, and System |
US 7,291,271 |
12/09/2003 |
Meso-frequency traveling electro-kinetic continuous adsorption system |
Note 2
http://www.who.int/respiratory/copd/en/
Note 3
http://www.inogen.com/resources/oxygen-concentrators/oxygen-tanks-vs-oxygen-concentrators/
Note 4
https://www.faa.gov/about/initiatives/cabin_safety/portable_oxygen/
Note 5
http://www.medgadget.com/2017/02/portable-oxygen-concentrator-market-size-at-744-million-in-2014-is-expected-grow-to-2-2-billion-by-2021.html
